Date: 2015-07-14
Type of information: Nomination
Compound:
Company: Noxxon Pharma (Germany)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 14, 2015, Noxxon Pharma has appointed Dr. Aram Mangasarian as the new CEO. He is taking over from Iain Buchanan, who will be nominated to join the Supervisory Board as a non-executive director. Aram Mangasarian joined Noxxon in May 2010 where he has led business development as Chief Business Officer, working closely with Iain Buchanan on the Executive Committee of the Company. Iain Buchanan, who took up his role as CEO of the company in September 2010, steps down from the operational day-to-day business, but will continue to work with the management team before he will rejoin the Supervisory Board as non-executive director. Aram Mangasarian has over 15 years experience in biotechnology and pharmaceutical business development. During the last 5 years he worked as CBO for Noxxon. He began his career at ExonHit Therapeutics (now Diaxonhit) in May 2000, eventually heading the business development function as Vice-President. He concluded a number of important agreements for ExonHit, in particular the strategic alliance with Allergan. In October 2005 Aram Mangasarian joined Novexel as Vice-President Business Development. In this capacity he concluded the licensing agreement for North American rights to the NXL104 beta-lactamase inhibitor with Forest Laboratories in January 2008, which provided for a €75m upfront payment, €75m in pre-commercial mile-stones and double-digit royalties. Aram Mangasarian was also a member of the team that negotiated the acquisition of Novexel by AstraZeneca in March 2010 for up to $505m.
Financial terms:
Latest news:
